Growth rates in US markets will decline: Dr Reddy's

Patent expiries, which peaked this year, will decrease over the next few years, says CEO G V Prasad

Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories Limited (DRL) today said that the company’s in the was going to decline as patent expiries peaked this year.

“US will continue to drive the growth in the current year. However, patent expiries peaked this year and will decrease over the next few years. As a result, growth rates will decline,” DRL vice-chairman and chief executive officer, G V Prasad, told the annual general meeting here on Friday.

However, he assured the shareholders that the company will come up with strategies to protect the bottom line from the impact of this revenue slowdown in the US market.

They management’s outlook on the throws up a significant challenge to the company in terms of sustaining the growth in the near to medium-term as US forms the single-largest market, contributing 45% to the total revenues and 36% to the net profit last year.

While Prasad holds the to drive the company’s growth in the global generics revenues this year, the first quarter results announced by the company yesterday showed a 27% growth in revenue from North America as compared to a full-year growth of 68% from the in 2011-12.

The company yesterday said that it would improve the in the by undertaking more number of launches, particularly in the second half of the current financial year.

About 42% of the total global generic drug revenues of Rs 1,906 crore for the quarter ended June 2012 had come from the US market, a two% increase over the corresponding previous quarter.

image
Business Standard
177 22
Business Standard

Growth rates in US markets will decline: Dr Reddy's

Patent expiries, which peaked this year, will decrease over the next few years, says CEO G V Prasad

BS Reporter  |  Hyderabad 



Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories Limited (DRL) today said that the company’s in the was going to decline as patent expiries peaked this year.

“US will continue to drive the growth in the current year. However, patent expiries peaked this year and will decrease over the next few years. As a result, growth rates will decline,” DRL vice-chairman and chief executive officer, G V Prasad, told the annual general meeting here on Friday.

However, he assured the shareholders that the company will come up with strategies to protect the bottom line from the impact of this revenue slowdown in the US market.

They management’s outlook on the throws up a significant challenge to the company in terms of sustaining the growth in the near to medium-term as US forms the single-largest market, contributing 45% to the total revenues and 36% to the net profit last year.



While Prasad holds the to drive the company’s growth in the global generics revenues this year, the first quarter results announced by the company yesterday showed a 27% growth in revenue from North America as compared to a full-year growth of 68% from the in 2011-12.

The company yesterday said that it would improve the in the by undertaking more number of launches, particularly in the second half of the current financial year.

About 42% of the total global generic drug revenues of Rs 1,906 crore for the quarter ended June 2012 had come from the US market, a two% increase over the corresponding previous quarter.

RECOMMENDED FOR YOU

Growth rates in US markets will decline: Dr Reddy's

Patent expiries, which peaked this year, will decrease over the next few years, says CEO G V Prasad

Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories Limited (DRL) today said that the company’s revenue growth in the US market was going to decline as patent expiries peaked this year.

Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories Limited (DRL) today said that the company’s in the was going to decline as patent expiries peaked this year.

“US will continue to drive the growth in the current year. However, patent expiries peaked this year and will decrease over the next few years. As a result, growth rates will decline,” DRL vice-chairman and chief executive officer, G V Prasad, told the annual general meeting here on Friday.

However, he assured the shareholders that the company will come up with strategies to protect the bottom line from the impact of this revenue slowdown in the US market.

They management’s outlook on the throws up a significant challenge to the company in terms of sustaining the growth in the near to medium-term as US forms the single-largest market, contributing 45% to the total revenues and 36% to the net profit last year.

While Prasad holds the to drive the company’s growth in the global generics revenues this year, the first quarter results announced by the company yesterday showed a 27% growth in revenue from North America as compared to a full-year growth of 68% from the in 2011-12.

The company yesterday said that it would improve the in the by undertaking more number of launches, particularly in the second half of the current financial year.

About 42% of the total global generic drug revenues of Rs 1,906 crore for the quarter ended June 2012 had come from the US market, a two% increase over the corresponding previous quarter.

image
Business Standard
177 22
Widgets Magazine

More News

  • Foreign investors make a strong comeback Chinese firms invested $2.3 billion in 3 months in India
  • IDBI Bank opts for AT-1 bonds to raise Rs 1,500 cr IDBI Bank raises Rs 1,500 cr via tier I bonds
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard